New York, NY – For decades, the presence of large numbers of regulatory T (Treg) cells in most solid tumors has been a harbinger of grim prognoses. These potent immune suppressors, acting as the body’s natural brakes on its own defenses, are widely known to weaken the immune system’s ability to mount an effective attack against cancer. Yet, colorectal cancer has long stood as a perplexing exception, a medical anomaly where a higher count of these very same Treg cells paradoxically correlates with improved patient survival. This enduring mystery has baffled researchers, obscuring potential therapeutic pathways and highlighting a fundamental gap in our understanding of cancer immunology.
Now, groundbreaking research from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally offered a clear, compelling explanation for this persistent paradox. Published in the prestigious scientific journal Immunity, the study reveals that the conventional view of Treg cells as a monolithic entity is fundamentally flawed, particularly within the context of colorectal cancer. The key discovery is not merely the quantity of Treg cells, but their inherent diversity – specifically, the existence of two distinct subtypes that play diametrically opposing roles in tumor progression. This paradigm shift in understanding not only resolves a long-standing enigma but also opens promising new avenues for improving immunotherapy, particularly for the vast majority of colorectal cancer patients who currently have limited options, and potentially for other cancers arising in barrier tissues such as the skin, stomach, mouth, and throat.
“Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it,” explains Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. Dr. Rudensky, a revered figure in the field of immunology, underscores the critical distinction: “It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches.” This revelation marks a pivotal moment, shifting the focus from broad-spectrum immune suppression to targeted modulation.
The Enigmatic Role of Regulatory T Cells in Cancer Immunity
To fully appreciate the significance of MSK’s latest findings, it’s crucial to understand the established role of regulatory T cells within the immune system. Treg cells are a specialized subset of T lymphocytes, integral to maintaining what is known as "immune tolerance." Their primary function is to prevent autoimmune diseases by distinguishing between harmful foreign invaders and the body’s own healthy cells, as well as harmless commensal microbes and everyday foods. They act as peacekeepers, dampening excessive immune responses that could otherwise lead to self-inflicted damage.
However, this beneficial function is often co-opted by cancer. In many solid tumors, Treg cells infiltrate the tumor microenvironment, where they actively suppress the anti-tumor activity of other immune cells, such as cytotoxic CD8+ T cells and natural killer (NK) cells, which are crucial for eradicating cancer cells. By effectively "putting the brakes" on the immune response, Treg cells create an immunosuppressive shield around the tumor, allowing it to grow unchecked. This general principle has led to the common understanding that a higher abundance of Treg cells in a tumor typically indicates a worse prognosis for the patient.
The colorectal cancer paradox, where increased Treg numbers correlated with better outcomes, thus presented a profound challenge to this established dogma. For years, researchers grappled with this inconsistency, unable to reconcile it with the broader understanding of Treg cell biology in oncology. The MSK study now provides the long-awaited clarity, demonstrating that the simplistic numerical count of Tregs belied a crucial functional heterogeneity.
Decades of Pioneering Research Culminate in Breakthrough
This landmark study is not an isolated discovery but the culmination of more than two decades of dedicated research by Dr. Alexander Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His pioneering work has been instrumental in establishing the fundamental principles of Treg cell biology, including their developmental pathways, intricate mechanisms of function, and their profound influence on various physiological and pathological processes, including cancer development. His lab has systematically uncovered how Treg cells are generated, how they exert their suppressive effects, and how they modulate immune responses across a spectrum of diseases.
The current study was spearheaded by an impressive team of lead authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now affiliated with the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher working under the joint mentorship of computational biologist Christina Leslie, PhD, who served as the study’s other senior author. This interdisciplinary collaboration, bridging immunology with advanced computational biology, was crucial for deciphering the complex cellular landscapes within tumor environments.
Focusing on the Most Prevalent Form of Colorectal Cancer
Colorectal cancer remains a formidable health challenge globally. According to the American Cancer Society, it is the second leading cause of cancer-related death when men and women are considered together, underscoring the urgent need for more effective treatments. The MSK researchers strategically focused their investigation on the most common form of the disease: microsatellite stable (MSS) with proficient mismatch repair (MMRp) tumors. This subtype accounts for a substantial 80% to 85% of all colorectal cancers.
Unfortunately, this prevalent group of cancers is notoriously difficult to treat with current immunotherapies, particularly checkpoint inhibitors. These therapies, which unleash the immune system by removing its natural brakes, have shown limited efficacy in MSS-MMRp colorectal cancers. This stands in stark contrast to microsatellite instability-high (MSI-H) and mismatch repair deficient (MMRd) colorectal cancers, a much smaller subset, which have demonstrated remarkable responses to checkpoint inhibitors, often allowing patients to avoid aggressive surgery, chemotherapy, and radiation. The unmet need for effective immunotherapeutic strategies in the MSS-MMRp population made this research particularly critical, aiming to extend the benefits of immunotherapy to a much broader patient demographic.
A Tale of Two Treg Subtypes: Opposing Forces Within the Tumor Microenvironment
To meticulously dissect the unique immune landscape of common colorectal cancers, the research team employed a sophisticated mouse model specifically developed at MSK. This model faithfully recapitulates the genetic alterations, behavioral characteristics, and intricate immune environment observed in human colorectal tumors, providing a highly relevant platform for studying disease progression and therapeutic interventions.
Through detailed analysis, the researchers made a pivotal discovery: tumor-associated Treg cells are not homogenous but segregate into two primary functional groups. The defining characteristic separating these groups was the production of a specific signaling molecule, or cytokine, called interleukin-10 (IL-10). One group of Treg cells produced IL-10, while the other did not.
The team then embarked on a series of rigorous experiments involving the selective removal of each of these Treg groups, meticulously observing their differential effects on tumor growth. The results were striking and unequivocally demonstrated their opposing roles:
-
IL-10-positive Treg cells (The Beneficial Regulators): These cells were found to actively slow tumor growth. Their mechanism of action involved reducing the activity of Th17 cells, another type of immune cell that produces interleukin-17 (IL-17). Importantly, IL-17 is known to act as a growth signal for various tumors, including colorectal cancer. By suppressing Th17 cells and, consequently, IL-17 production, the IL-10-positive Tregs effectively deprive the tumor of a crucial growth stimulus. These protective Treg cells were observed to be more commonly located in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining local immune homeostasis. When these beneficial IL-10-positive Treg cells were experimentally removed, tumors exhibited a discernible acceleration in growth, directly demonstrating their tumor-restraining effect.
-
IL-10-negative Treg cells (The Harmful Suppressors): In stark contrast, the IL-10-negative Treg cells exerted the opposite effect, actively promoting tumor growth. These cells were found to powerfully suppress the activity of crucial anti-cancer immune defenders, most notably cytotoxic CD8+ T cells, which are renowned for their ability to recognize and destroy cancer cells. This harmful subtype was predominantly localized within the tumor itself, strategically positioned to neutralize the immune system’s direct assault on cancer cells. When these detrimental IL-10-negative Treg cells were selectively eliminated, tumors significantly regressed and became smaller, confirming their role as drivers of tumor progression.
“This research shows how important these positive cells are,” states Dr. Huang, highlighting the necessity of distinguishing between the two populations. “And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones.” This sentiment encapsulates the essence of the new paradigm: moving beyond blunt immunosuppression to a nuanced, targeted approach.
Clinical Validation: Patient Data Corroborates Experimental Findings
The compelling results from the mouse models were not confined to preclinical settings. The MSK team meticulously validated their findings using tumor samples obtained from human colorectal cancer patients. In these clinical samples, they successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells, confirming the direct relevance of their mouse model observations to human disease.
Further strengthening their conclusions, the researchers conducted an extensive analysis of clinical outcomes for over 100 colorectal cancer patients. The correlation was clear and striking: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells experienced significantly longer survival times. Conversely, patients whose tumors harbored a greater proportion of the harmful IL-10-negative Treg cells faced poorer clinical outcomes. This robust patient data unequivocally confirms the differential impact of these Treg subtypes, transforming a laboratory discovery into a clinically relevant insight.
Charting a New Therapeutic Course: Targeting CCR8 for Selective Treg Depletion
The profound insights gleaned from this study immediately suggest a promising and precise path forward for improving treatment strategies for the majority of colorectal cancer patients, particularly those with MSS-MMRp tumors who currently lack effective immunotherapeutic options.
A critical finding was that the harmful IL-10-negative Treg cells, those primarily located within tumors and responsible for suppressing the anti-tumor immune response, express exceptionally high levels of a specific protein on their surface known as CCR8. This cell-surface receptor acts as a unique molecular signature for these detrimental cells.
This discovery builds upon earlier foundational work from Dr. Rudensky’s lab, specifically led by breast cancer surgeon George Plitas, MD. Their previous research had already identified CCR8 as highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. That groundbreaking work had initially proposed that antibodies designed to specifically target and deplete CCR8-expressing cells could offer a novel therapeutic strategy. Such an approach would allow for the selective removal of harmful Treg cells from the tumor microenvironment, thereby unleashing the immune system to more effectively attack the cancer, all while preserving the beneficial Treg cells that contribute to immune homeostasis in healthy tissues.
“This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic,” Dr. Rudensky affirms, highlighting the international scientific community’s recognition of this innovative strategy.
Indeed, the promise of CCR8-targeting therapies is already being translated into clinical investigation. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this approach both as a monotherapy and in combination with existing immunotherapies. The new MSK study provides compelling additional evidence, strengthening the rationale for deploying this precision strategy specifically in colorectal cancer, and potentially extending its application to a broader spectrum of malignancies.
Beyond Colorectal Cancer: Broader Horizons for Immunotherapy
The implications of the MSK study extend beyond colorectal cancer. The researchers undertook a comprehensive examination of a vast dataset comprising T cells from 16 different cancer types. Their objective was to ascertain whether the same critical immune patterns, specifically the division between IL-10-positive and IL-10-negative Treg cells, could be observed elsewhere.
Remarkably, they found similar distinctions in several cancers that originate in what are known as "barrier tissues." These include various cancers affecting the skin, as well as the delicate linings of the mouth, throat, and stomach.
“What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses,” explains Dr. Mitra, who played a leading role in the complex data analysis for the study and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared characteristic of constant immune surveillance and repair in barrier tissues suggests a conserved immunological mechanism where the dual roles of Treg cells might be particularly relevant.
The team posits that the therapeutic strategies designed to selectively remove IL-10-negative Treg cells in colorectal cancer, particularly those targeting CCR8, could also prove effective against these other cancers that arise in analogous barrier tissues. This opens up an exciting prospect for a broad-reaching immunotherapy platform, moving towards a more unified approach to treating certain categories of solid tumors.
The Shifting Landscape of Metastatic Disease
Adding another layer of crucial nuance, the researchers also investigated the immune landscape in colorectal cancer that had metastasized, specifically to the liver. They observed a markedly different immune pattern in these advanced-stage tumors.
In these metastatic lesions, the harmful IL-10-negative Treg cells were found to vastly outnumber the beneficial IL-10-positive cells. This imbalance suggested a shift in the overall Treg cell composition, favoring the immune-suppressive subtype. Consequently, unlike in primary tumors where selective targeting is paramount, removing all Treg cells in this metastatic context resulted in the shrinkage of the tumors.
This critical finding highlights that disease stage and anatomical location can profoundly influence the immune microenvironment and, therefore, the optimal therapeutic strategy. It underscores the necessity for precision medicine approaches that account for both the tissue of origin and the stage of disease progression, cautioning against a one-size-fits-all approach to Treg-targeting therapies.
A Future of Precision Immunotherapy
The groundbreaking research from Memorial Sloan Kettering Cancer Center represents a significant leap forward in our understanding of cancer immunology and immunotherapy. By resolving the long-standing colorectal cancer paradox, the study illuminates the crucial heterogeneity of regulatory T cells, demonstrating that these immune regulators are not uniformly detrimental but can play context-dependent, opposing roles in tumor progression.
The identification of CCR8 as a specific marker for the harmful, tumor-promoting Treg subtype offers a tangible and highly promising therapeutic target. This paves the way for the development of precision immunotherapies, such as CCR8-depleting antibodies, that can selectively disarm the tumor’s immune defenses without compromising beneficial immune functions. This selective approach holds immense potential to improve outcomes for a large population of colorectal cancer patients, particularly those with MSS-MMRp tumors who currently face limited effective immunotherapy options.
Moreover, the discovery of similar immune patterns in other barrier tissue cancers suggests a broader applicability for this innovative strategy, potentially extending its benefits to patients with skin, oral, pharyngeal, and gastric cancers. While the complexities of metastatic disease highlight the need for adaptable strategies, the overall trajectory of this research points towards a future of highly personalized and effective cancer immunotherapies, built upon a foundation of deep scientific understanding and decades of dedicated effort.
Authors, Funding, and Disclosures
In addition to the lead and senior authors, the research team included Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key contributions to the research were provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, underscoring the collaborative and technologically advanced environment that fostered this breakthrough.
Funding for this pivotal study was generously provided by a consortium of esteemed organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
In the interest of transparency, Dr. Alexander Rudensky has disclosed his affiliations and financial interests. He serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. George Plitas are inventors on patents and patent applications held by MSK pertaining to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8. These disclosures reflect the intricate relationship between groundbreaking academic research and its translation into potential clinical innovations.
About the Author
